Real people. Real insight. Real value.
Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.
We invest predominantly in early and mid-stage life sciences companies. We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.
Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.
Advent Life Sciences. Innovation. Clarity. Execution.
-

Celgene to Acquire Avila Therapeutics
Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases
-

Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies
-

CN Creative - Intellicig Electronic Cigarettes on ITV show "This Morning"
Linda Robson's comment as she was handed an Intellicig to try on the 'This Morning' show on ITV said it all; "Fantastic!" she exclaimed.
-

Biocartis completes EUR 71 million (USD 100 million) Series C Fund Raising